Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 15c; Offers FY23 Revenue Guidance

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.46), $0.15 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $95.3 million versus the consensus estimate of $91.4 million.

GUIDANCE:

Intra-Cellular Therapies sees FY2023 revenue of $430-455 million, versus the consensus of $448 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Worthington Industries (WOR) Misses Q4 EPS by 9c
• Nike names former Pfizer CFO David Denton as new finance chief